Hourcade-Potelleret F - Search Results

1

Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.

Assouline S, Buccheri V, Delmer A, Gaidano G, McIntyre C, Brewster M, Catalani O, Hourcade-Potelleret F, Sayyed P, Badoux X. Assouline S, et al. Br J Clin Pharmacol. 2015 Nov;80(5):1001-9. doi: 10.1111/bcp.12662. Epub 2015 Jul 29. Br J Clin Pharmacol. 2015. PMID: 25900065 Free PMC article. Clinical Trial.

2

Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study.

Salar A, Avivi I, Bittner B, Bouabdallah R, Brewster M, Catalani O, Follows G, Haynes A, Hourcade-Potelleret F, Janikova A, Larouche JF, McIntyre C, Pedersen M, Pereira J, Sayyed P, Shpilberg O, Tumyan G. Salar A, et al. J Clin Oncol. 2014 Jun 10;32(17):1782-91. doi: 10.1200/JCO.2013.52.2631. Epub 2014 May 12. J Clin Oncol. 2014. PMID: 24821885 Clinical Trial.

3

Development of a subcutaneous formulation for trastuzumab - nonclinical and clinical bridging approach to the approved intravenous dosing regimen.

Bittner B, Richter WF, Hourcade-Potelleret F, McIntyre C, Herting F, Zepeda ML, Schmidt J. Bittner B, et al. Arzneimittelforschung. 2012 Sep;62(9):401-9. doi: 10.1055/s-0032-1321831. Epub 2012 Aug 23. Arzneimittelforschung. 2012. PMID: 22918857 Review.

4

Use of a population pharmacokinetic approach for the clinical development of a fixed-dose subcutaneous formulation of trastuzumab.

Hourcade-Potelleret F, Lemenuel-Diot A, McIntyre C, Brewster M, Lum B, Bittner B. Hourcade-Potelleret F, et al. CPT Pharmacometrics Syst Pharmacol. 2014 Jan 2;3(1):e87. doi: 10.1038/psp.2013.63. CPT Pharmacometrics Syst Pharmacol. 2014. PMID: 25019376 Free PMC article.

5

Non-clinical pharmacokinetic/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab.

Bittner B, Richter WF, Hourcade-Potelleret F, Herting F, Schmidt J. Bittner B, et al. Drug Res (Stuttg). 2014 Nov;64(11):569-75. doi: 10.1055/s-0033-1363993. Epub 2014 Jan 22. Drug Res (Stuttg). 2014. PMID: 24452524 Review.

6

Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.

Cartron G, Hourcade-Potelleret F, Morschhauser F, Salles G, Wenger M, Truppel-Hartmann A, Carlile DJ. Cartron G, et al. Haematologica. 2016 Feb;101(2):226-34. doi: 10.3324/haematol.2015.133421. Epub 2015 Dec 11. Haematologica. 2016. PMID: 26659915 Free PMC article. Clinical Trial.

7

Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor.

Tian X, Zhang H, Heimbach T, He H, Buchbinder A, Aghoghovbia M, Hourcade-Potelleret F. Tian X, et al. J Clin Pharmacol. 2018 Dec;58(12):1533-1540. doi: 10.1002/jcph.1312. Epub 2018 Sep 4. J Clin Pharmacol. 2018. PMID: 30179260 Review.

8

Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.

Bauer S, Demetri GD, Halilovic E, Dummer R, Meille C, Tan DSW, Guerreiro N, Jullion A, Ferretti S, Jeay S, Van Bree L, Hourcade-Potelleret F, Wuerthner JU, Fabre C, Cassier PA. Bauer S, et al. Among authors: hourcade potelleret f. Br J Cancer. 2021 Aug;125(5):687-698. doi: 10.1038/s41416-021-01444-4. Epub 2021 Jun 17. Br J Cancer. 2021. PMID: 34140638 Free PMC article. Clinical Trial.

9

Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment.

Hoch M, Sato M, Zack J, Quinlan M, Sengupta T, Allepuz A, Aimone P, Hourcade-Potelleret F. Hoch M, et al. Among authors: hourcade potelleret f. J Clin Pharmacol. 2021 Nov;61(11):1454-1465. doi: 10.1002/jcph.1926. Epub 2021 Jul 16. J Clin Pharmacol. 2021. PMID: 34115385 Clinical Trial.

10

Pharmacokinetics of Asciminib When Taken With Imatinib or With Food.

Hoch M, Zack J, Quinlan M, Huth F, Forte S, Dodd S, Aimone P, Hourcade-Potelleret F. Hoch M, et al. Among authors: hourcade potelleret f. Clin Pharmacol Drug Dev. 2022 Feb;11(2):207-219. doi: 10.1002/cpdd.1019. Epub 2021 Oct 5. Clin Pharmacol Drug Dev. 2022. PMID: 34609077

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19 results

Search Page

Filters